[加泰罗尼亚胃肠病学会立场文件：三联疗法治疗1型慢性丙型肝炎病毒] - Suppr | 超能文献

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

作者信息

Bruguera Miquel, Esteban Rafael, Forns Xavier, Planas Ramón, Quer Juan Carlos, Solà Ricard, Vergara Mercè

机构信息

Hospital Clínic, Barcelona, España.

出版信息

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

DOI:10.1016/j.gastrohep.2012.03.005

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].[加泰罗尼亚胃肠病学会立场文件：三联疗法治疗1型慢性丙型肝炎病毒]

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3.

2

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.基于丙型肝炎病毒蛋白酶抑制剂的三联疗法对慢性丙型肝炎1型感染的影响。

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934.

3

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].特拉匹韦的临床应用：停药规则、预测反应、治疗时长及不良反应管理

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:19-25. doi: 10.1016/S0213-005X(13)70120-4.

4

[Conclusions].[结论]。

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:49-50. doi: 10.1016/S0213-005X(13)70124-1.

5

Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.两种实时荧光定量PCR检测方法对接受蛋白酶抑制剂治疗的慢性丙型肝炎患者的临床意义

PLoS One. 2017 Jan 24;12(1):e0170667. doi: 10.1371/journal.pone.0170667. eCollection 2017.

6

Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.信件：特拉匹韦三联疗法用于接受血液透析的慢性丙型肝炎1型患者

Aliment Pharmacol Ther. 2014 Jun;39(11):1342-4. doi: 10.1111/apt.12748.

7

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.蛋白酶抑制剂治疗慢性丙型肝炎基因型 1 感染：新的治疗标准。

Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29.

8

[Therapy of chronic Hepatitis C in 2008].[2008年慢性丙型肝炎的治疗]

MMW Fortschr Med. 2008 Mar 27;150(13):31-4. doi: 10.1007/BF03365407.

9

Telaprevir for the treatment of chronic hepatitis C infection.替拉瑞韦治疗慢性丙型肝炎感染。

Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14. doi: 10.1586/eri.11.133.

10

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?三联疗法治疗第一代 HCV 蛋白酶抑制剂：先导期或无先导期？

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

引用本文的文献

1

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.基线病毒遗传异质性和宿主因素与丙型肝炎病毒 1b 感染患者治疗结果预测的相关性。

PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600. eCollection 2013.